[New drug approval: Olaparib and niraparib - first line in ovarian cancer].
作者信息
Delaye Matthieu, Rodrigues Manuel
机构信息
Institut Curie, hôpital René-Huguenin, département d'oncologie médicale, 35, rue Dailly, 92210 Saint-Cloud, France; Association pour l'enseignement et la recherche des internes en oncologie (AERIO), 149, avenue du Maine, 75014 Paris, France.
Institut Curie, PSL research university, département d'oncologie médicale, 26, rue d'Ulm, 75005 Paris, France; Institut Curie, PSL research university, Inserm U830, 26, rue d'Ulm, 75005 Paris, France.
出版信息
Bull Cancer. 2021 Apr;108(4):350-351. doi: 10.1016/j.bulcan.2021.01.003. Epub 2021 Feb 26.
PMID:33641880
Abstract
摘要
相似文献
1
[New drug approval: Olaparib and niraparib - first line in ovarian cancer].[新药获批：奥拉帕利和尼拉帕利——卵巢癌一线治疗用药]
Bull Cancer. 2021 Apr;108(4):350-351. doi: 10.1016/j.bulcan.2021.01.003. Epub 2021 Feb 26.
2
Budget impact analysis of niraparib and olaparib for maintenance treatment of platinum-sensitive, recurrent ovarian cancer in the US.尼拉帕利和奥拉帕利用于美国铂敏感复发性卵巢癌维持治疗的预算影响分析
J Med Econ. 2019 Feb;22(2):187-195. doi: 10.1080/13696998.2018.1557199. Epub 2019 Jan 4.
3
Traitement médical de première ligne du cancer épithélial de l'ovaire de haut grade: First-line medical treatment of high-grade epithelial ovarian cancer.高级别上皮性卵巢癌的一线医学治疗。
Bull Cancer. 2021 Dec;108(9S1):S5-S12. doi: 10.1016/S0007-4551(21)00582-8.
4
Cost-Effectiveness of Niraparib and Olaparib as Maintenance Therapy for Patients with Platinum-Sensitive Recurrent Ovarian Cancer.尼拉帕利和奥拉帕利作为铂类敏感复发性卵巢癌维持治疗的成本效益。
J Manag Care Spec Pharm. 2018 Dec;24(12):1219-1228. doi: 10.18553/jmcp.2018.24.12.1219.
5
PARP inhibitors for ovarian cancer.用于卵巢癌的聚（ADP - 核糖）聚合酶抑制剂
Med Lett Drugs Ther. 2017 Dec 4;59(1535):200-202.
6
Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer.使用 PARP 抑制剂治疗卵巢癌患者。
Curr Treat Options Oncol. 2018 Nov 15;19(12):1. doi: 10.1007/s11864-018-0572-7.
7
[PARP inhibitors in first-line of ovarian cancers].[聚（ADP-核糖）聚合酶抑制剂用于卵巢癌一线治疗]
Bull Cancer. 2020 Jan;107(1):4-5. doi: 10.1016/j.bulcan.2019.10.009. Epub 2020 Jan 10.
8
Olaparib for the treatment of ovarian cancer.奥拉帕利用于治疗卵巢癌。
Drugs Today (Barc). 2016 Jan;52(1):17-28. doi: 10.1358/dot.2016.52.1.2440714.
9
Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.使用 PARP 抑制剂治疗卵巢癌的进展及耐药的潜在机制。
Curr Drug Targets. 2020;21(2):167-178. doi: 10.2174/1389450120666190925123507.
10
Budget impact of niraparib as maintenance treatment in recurrent ovarian cancer following platinum-based chemotherapy.尼拉帕利作为基于铂类化疗后的复发性卵巢癌维持治疗的预算影响。
J Comp Eff Res. 2019 Jun;8(8):577-587. doi: 10.2217/cer-2018-0069. Epub 2019 Apr 2.
Zotero 插件